Clinical significance and management of Barrett’s esophagus with epithelial changes indefinite for dysplasia

Table 3 Risk of Incident neoplasia in patients with Barrett’s esophagus with epithelial change indefinite for dysplasia

Ref.	No. of cases	Follow up in months (range)	Incident LGD n (%)	Incident HGD n (%)	Incident adeno carcinoma n (%)	Incident advanced neoplasia (per 100 person-years	Risk factors for progression to advanced neoplasia
Duits et al[13], 2015	40	Median 31 (16-59)	0	1 (2.5)	0 (0)	0.9	Not done
Horvath et al[12], 2015	82	Mean 59 (13-182)	14 (8.3)	3 (2.3)	2 (2.3)	1.2	p53 expression in >5% nuclei
Kestens et al[15], 2015	631	Not known	No data	10 (1.6)	6 (1.0)	0.43	Older age
Sinh et al[16], 2015	83	Mean 68.4 (SD: 37.2)	No data	3 (3.6)	1 (1.2)	0.86	Not done for BE IND group
Sonwalkar et al[9], 2010	37	Median 38.7 (6-122)	3 (8.1)	0 (0)	3 (8.1)	Not done	Expression of AMACR in more than 1% of cells

BE IND: Barrett’s esophagus with epithelial change indefinite for dysplasia; LGD: Low-grade dysplasia; HGD: High-grade dysplasia; SD: Standard deviation; AMACR: Alpha-methylacyl-CoA racemase.